The role of male foetal sex on maternal and neonatal outcomes in pregnancies complicated by gestational diabetes-secondary analysis of a randomised placebo controlled clinical trial of metformin in gestational diabetes (EMERGE)
Abstract
Background Male foetal sex is recognised as an independent risk factor for adverse pregnancy outcomes including preterm birth, neonatal care unit admission and lower Apgar scores. Male foetuses appear to increase the risk of maternal gestational diabetes in the mother due to impacts on beta cell function, and in pregnancies impacted by gestational diabetes, male offspring have higher rates of hypoglycaemia, respiratory distress and macrosomia. Metformin exposure in animal models has also demonstrated sex-specific effects with different patterns in adiposity and lipid levels observed between male and female offspring exposed to metformin in utero. The aim of this analysis is to determine whether foetal sex modifies maternal and neonatal outcomes in gestational diabetes, and evaluate the sex-specific response to metformin on insulin usage, fasting glucose at 32 and 38 weeks and foetal size. Methods We conducted a secondary analysis of the Early Metformin in Gestational Diabetes (EMERGE) randomised controlled trial and analysed neonatal outcomes according to sex and metformin exposure. Results At randomisation, women carrying a male foetus had a higher plasma glucose at 60 min on oral glucose tolerance testing (9.69 vs. 9.37 mmol/L, p = 0.039). In exploratory analyses, metformin exposure in male pregnancies was associated with lower fasting glucose at 32 (4.88 vs. 5.01 mmol/L, p = 0.014) and 38 weeks (4.49 vs. 4.69 mmol/L, p = 0.002) and reduced insulin use (38% vs. 53%, p =…
How strong is the evidence?
Evidence Hub reads this as a secondary / pooled analysis, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.